Glycosmedia

Diabetes News Service

Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS

No overall statistically significant increased risk of bladder cancer in patients ever exposed to pioglitazone in a completed 10-year epidemiological study (Takeda)

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices

Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Website by Wired up Wales